Literature DB >> 33502877

Are clarithromycin, azithromycin and their analogues effective in the treatment of COVID19?

M A Gedikli, B Tuzun, A Aktas, K Sayin, H Ataseven.   

Abstract

BACKGROUND: SARS-CoV-2, which started in Wuhan and later affected the whole world, is the most important disease of the world today. Many ways to inhibit SARS-CoV-2 virus are sought to prevent the spread of this virus. Azithromycin and clarithromycin are considered for the treatment of the SARS-CoV-2 virus, which has a high similarity to previous colonic diseases. AIM: We aimed to determine whether azithromycin and clarithromycin, the RNA-dependent RNA polymerase protein inhibitor used in the treatment of COVID-19, is effective against SARS Cov-2 in silico. RESULTS AND
CONCLUSION: The 503 analogues of azithromycin and clarithromycin were studied to target SARS-CoV-2 the RNA-dependent RNA polymerase protein inhibition. Maestro program was used to compare the inhibition activities of these analogues. A detailed comparison was made using the numerical value of many parameters obtained. ADME / T properties were then examined to determine the effects and reactions of analogues on human metabolism. In this study, the SARS-CoV2 virus is 6NUR and 6NUS, which is the RNA-dependent RNA polymerase protein. Among these proteins, the best inhibitor among the 503 analogues according to the docking score parameter was 9851445 with a great difference. This analogue was an analogue of azithromycin (Tab. 3, Fig. 6, Ref. 58).

Entities:  

Keywords:  Azithromycin; Clarithromycin COVID19.; RNA-dependent RNA polymerase; SARS-CoV-2

Mesh:

Substances:

Year:  2021        PMID: 33502877     DOI: 10.4149/BLL_2021_015

Source DB:  PubMed          Journal:  Bratisl Lek Listy        ISSN: 0006-9248            Impact factor:   1.278


  2 in total

1.  Preparation and Characterization of Hydrophilic Polymer Based Sustained-Release Matrix Tablets of a High Dose Hydrophobic Drug.

Authors:  Niaz Ali Khan; Amjad Khan; Rooh Ullah; Majeed Ullah; Amal Alotaibi; Riaz Ullah; Adnan Haider
Journal:  Polymers (Basel)       Date:  2022-05-13       Impact factor: 4.967

2.  ADME properties, bioactivity and molecular docking studies of 4-amino-chalcone derivatives: new analogues for the treatment of Alzheimer, glaucoma and epileptic diseases.

Authors:  Meliha Burcu Gürdere; Yakup Budak; Umit M Kocyigit; Parham Taslimi; Burak Tüzün; Mustafa Ceylan
Journal:  In Silico Pharmacol       Date:  2021-05-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.